4.68
前日終値:
$4.79
開ける:
$4.82
24時間の取引高:
787.97K
Relative Volume:
1.00
時価総額:
$193.74M
収益:
$134.48M
当期純損益:
$-38.94M
株価収益率:
-4.9087
EPS:
-0.9534
ネットキャッシュフロー:
$-19.34M
1週間 パフォーマンス:
-4.68%
1か月 パフォーマンス:
-17.61%
6か月 パフォーマンス:
-63.32%
1年 パフォーマンス:
-66.78%
Rxsight Inc Stock (RXST) Company Profile
Compare RXST vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
RXST
Rxsight Inc
|
4.68 | 198.29M | 134.48M | -38.94M | -19.34M | -0.9534 |
|
ABT
Abbott Laboratories
|
90.62 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
310.58 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
81.32 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
|
BSX
Boston Scientific Corp
|
46.92 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
88.58 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | 開始されました | William Blair | Mkt Perform |
| 2025-07-15 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | ダウングレード | Jefferies | Buy → Hold |
| 2025-07-09 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-09 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-07-09 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | 開始されました | Piper Sandler | Neutral |
| 2025-04-09 | ダウングレード | UBS | Buy → Neutral |
| 2025-04-04 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2025-04-03 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-12-20 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-10-29 | 開始されました | Jefferies | Buy |
| 2024-08-20 | 繰り返されました | Needham | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-05-07 | 繰り返されました | BTIG Research | Buy |
| 2023-12-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | 開始されました | Stifel | Buy |
| 2023-12-04 | 開始されました | Morgan Stanley | Overweight |
| 2023-04-13 | 開始されました | Oppenheimer | Outperform |
| 2022-12-12 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | 開始されました | Needham | Buy |
すべてを表示
Rxsight Inc (RXST) 最新ニュース
RxSight, Inc. Hits 52-Week Low of $4.58 Amidst 92.2% Decline - MarketsMojo
RxSight, Inc. Stock Plummets to New 52-Week Low of $4.49 - Markets Mojo
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates - MSN
RxSight Inc. (RXST) Falters Near Support: Testing Key Levels After 1.96% DeclineDark Pool Sentiment - newsline.com
Understanding Momentum Shifts in (RXST) - Stock Traders Daily
RxSight, Inc. Hits 52-Week Low at $5.31 Amid Ongoing Struggles - MarketsMojo
RxSight, Inc. Hits 52-Week Low at USD 4.93 Amidst Ongoing Struggles - MarketsMojo
RxSight Inc. (RXST) Slides 3% as Stock Struggles Below Key Resistance at $5.03Hedge Fund Exposure - newsline.com
RxSight Inc. (RXST) Q1 2026 Earnings: EPS Miss Weighs on Shares Amid Operating ChallengesProfitability Analysis - newsline.com
RXST Technical Analysis & Stock Price Forecast - Intellectia AI
RxSight Inc stock (US78419L1008): Nasdaq-listed eye-care specialist in focus after recent price weak - AD HOC NEWS
RXST Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin; Stock DeclinesEarnings Call Highlights - newsline.com
RxSight Inc. (RXST) Slips 4.65% as Stock Challenges $5.06 Support LevelTICK Divergence - The Legal Advocate
RxSight Securities Lawsuit Advances After Court Denies Dismissal Bid - TipRanks
RXST Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Ramp-UpEPS Growth Rate - The Legal Advocate
Midday Stock Roundup: TTM Drops on Investor Day - Orange County Business Journal
RxSight Must Litigate Investor Suit Over Eye Lens System Demand - Bloomberg Law News
RXST: Premium IOL penetration grows as competitive headwinds ease and commercial focus intensifies - TradingView
Avoiding Lag: Real-Time Signals in (RXST) Movement - Stock Traders Daily
RxSight Inc. Q1 2026 Earnings: EPS Misses Estimates Amid Operational HeadwindsOne-Time Loss Impact - Newser
RxSight Q1 2026 Earnings: EPS Misses Estimates by 32% as Operational Costs WeighEarnings Beat Streak - The Legal Advocate
RxSight stock gains ahead of Stifel meeting, investors wait for signs of turnaround - Bez Kabli
RxSight to present at Stifel 2026 Virtual Ophthalmology Forum on May 26 - Pluang
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum - The Manila Times
RxSight stock (US78419L1008): Q1 revenue dip and share slide put growth story to the test - AD HOC NEWS
Tarsus, RxSight Fall Despite Growth Signals - Orange County Business Journal
RxSight stock (US78419L1008): FDA-linked growth and execution stay in focus - AD HOC NEWS
RxSight stock (US78419L1008): FDA-backed growth story stays in focus - AD HOC NEWS
Number of shareholders of RxSight, Inc. – NASDAQ:RXST - TradingView
Discipline and Rules-Based Execution in RXST Response - Stock Traders Daily
RxSight Earnings Call Balances Growth With Headwinds - TipRanks
TradingKey - TradingKey
BofA Securities Maintains RxSight(RXST.US) With Sell Rating - Moomoo
RXST: Stable Q1 results and ongoing commercial initiatives support sequential growth and global expansion - TradingView
Artisan Partners reports 5.0% stake in RxSight (NASDAQ: RXST) - Stock Titan
Midday Stock Roundup: Skyworks Solutions Falls - Orange County Business Journal
RxSight (RXST) Q1 2026 Earnings Transcript - AOL.com
RxSight, Inc. (NASDAQ:RXST) Q1 2026 Earnings Call Transcript - Insider Monkey
RxSight (RXST) Gets a Hold from Stifel Nicolaus - The Globe and Mail
William Blair Maintains RxSight(RXST.US) With Hold Rating - Moomoo
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook - VisionMonday.com
Piper Sandler Maintains RxSight(RXST.US) With Hold Rating, Maintains Target Price $10 - Moomoo
RxSight, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Rxsight Inc (RXST) 財務データ
収益
当期純利益
現金流量
EPS
Rxsight Inc (RXST) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Goldshleger Ilya | See remarks |
Sep 25 '25 |
Option Exercise |
4.27 |
23,445 |
99,998 |
65,691 |
大文字化:
|
ボリューム (24 時間):